Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua and Xin Medical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1 - The three products involved are Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all of which are used for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights related to the products [1] - The agreement is set for a duration of ten years, and Enhua will make a one-time non-refundable payment of $20 million as a licensing fee to the group [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. for exclusive commercialization rights of three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to Green Leaf [1] Group 2: Market Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence for schizophrenia treatment [1] - The agreement is expected to provide patients with more comprehensive treatment options in the schizophrenia market [1]

Core Viewpoint - Green Leaf Pharmaceutical has signed a collaboration agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China, aimed at enhancing treatment options for schizophrenia patients [1][2]. Group 1: Collaboration Agreement - The agreement includes three products: Rykotan (injectable risperidone microspheres), Rybale (paliperidone palmitate injection), and Meibiri (paliperidone palmitate injection), all intended for the treatment of schizophrenia [1]. - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1]. - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf upon signing the agreement, which has a duration of ten years [1]. Group 2: Market Context and Product Development - Schizophrenia is a chronic and highly recurrent disease, with approximately 8 million patients in China, making treatment adherence a significant challenge [2]. - Long-acting injectable antipsychotics, such as those developed by Green Leaf, significantly improve patient compliance compared to oral formulations, serving as an important strategy to prevent relapse [2]. - Rykotan is noted as China's first independently developed long-acting injectable second-generation antipsychotic, while Rybale is the world's first and only paliperidone long-acting injection with a "one injection in the first month" dosing regimen [2]. Group 3: Strategic Importance - The board believes that the three long-acting injectables create a differentiated product portfolio that addresses the treatment needs of schizophrenia patients across all stages of the disease [3]. - The CNS (central nervous system) sector is a core strategic area for Green Leaf, which possesses a competitive product matrix and platform capabilities in this field [3]. - The collaboration with Enhua aims to deepen the market presence in the CNS sector, particularly enhancing product coverage in primary healthcare centers to help more patients receive standardized treatment and reduce the burden of the disease [3].

Group 1 - Green Leaf Pharmaceutical has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] - The three products include Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all aimed at treating schizophrenia [1][2] - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical as part of the agreement, which lasts for ten years [1] Group 2 - Schizophrenia is a chronic, high-recurrence, and highly disabling disease, with approximately 8 million patients in China [2] - Long-acting injectable antipsychotics significantly improve patient compliance compared to oral formulations, making them an important treatment strategy for preventing relapse [2] - The products are developed based on Green Leaf's long-acting and sustained-release technology platform, with Riketu being the first domestically developed second-generation long-acting injectable antipsychotic in China [2] Group 3 - The board believes that the three long-acting injectables form a differentiated product portfolio that addresses the treatment needs of schizophrenia patients at all stages of the disease [3] - CNS (Central Nervous System) is a core strategic area for the company, which aims to accelerate the realization of product pipeline value through strategic partnerships [3] - The collaboration with Enhua will enhance the coverage of these products in primary healthcare centers, helping more patients receive standardized treatment and reduce the burden of the disease [3]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua Xinyi Pharmaceutical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights, as well as responsibility for production and supply [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to the group [1] Group 2: Strategic Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence in schizophrenia treatment and provide more comprehensive treatment options for patients [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186) saw a nearly 3% increase in stock price, currently at HKD 3.09, with a trading volume of HKD 8.3751 million, following the announcement of five new products being included in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] Group 1 - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Catalog and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] - The new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) which are newly included in the National Medical Insurance Catalog [1] - Zanbija (Injectable Lurbinectedin) which has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1] - Baituowei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) which have successfully renewed their inclusion in the National Medical Insurance Catalog [1]